ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 9, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 9, 2011
News
FDA Office of Compliance to Become a Super Office
By Angie Drakulich
CDER Director Janet Woodcock announces reorganization.
J&J Ordered to Pay $327 Million Penalty in False-Claim Suit
By Amy Ritter
A South Carolina court found that a subsidiary of Johnson & Johnson violated state consumer protection laws by using misleading marketing for its antipsychotic drug, Risperdal.
US Supreme Court Rules in Favor of Roche in University Patent-Rights Case
By Patricia Van Arnum
The US Supreme Court ruled in favor of Roche in a patent-dispute case the pharmaceutical company had with Stanford University in a 7-2 vote.
AstraZeneca Settles Sex-Discrimination Lawsuit
By Erik Greb
AstraZeneca agreed to settle a sex-discrimination lawsuit by paying $250,000 to 124 women who worked at the company's Philadelphia Business Center.
Alliance Calls for European Pricing Transparency
By Stephanie Sutton
The European Public Health Alliance has called for greater pricing transparency, as well as the formation of a public website that provides comparative information on medicines' procurement prices.
Week of June 9, 2011: Company and People Notes: Aveo Forms Drug-Development Pact with Centocor; GPhA Appoints Jim Fenton as Senior Vice-President of Government Affairs; and More.
Aveo Forms Drug-Development Pact with Centocor Ortho Biotech; Generic Pharmaceutical Association Appoints Jim Fenton as Senior Vice-President of Government Affairs; and More.
Regulatory Roundup: FDA Issues Final Guidance to Amend IND Reporting Requirements
FDA Issues Final Guidance to Amend IND Reporting Requirements.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here